International Edition
Latest News
Health

GLP-1 Medications and Reproductive Health: Guidelines for Patients of Childbearing Age

Nearly 25 million US women of reproductive age are eligible for GLP-1 medications, according to clinical data that bring popular weight-loss drugs directly into primary care and OB/GYN clinics. More than 40% of all pregnancies in the country…

GLP-1 Medications and Reproductive Health: Guidelines for Patients of Childbearing Age

Nearly 25 million US women of reproductive age are eligible for GLP-1 medications, according to clinical data that bring popular weight-loss drugs directly into primary care and OB/GYN clinics.

More than 40% of all pregnancies in the country are unplanned, creating new clinical complexities for patients taking treatments like semaglutide and tirzepatide during their childbearing years.

New consensus guidelines published in Obesity Reviews outline how clinicians must manage metabolic health, contraception, and preconception planning. Patients at the highest risk for an unplanned pregnancy are those with substantial metabolic burdens or ovulatory dysfunction, particularly individuals with polyendocrine metabolic ovarian syndrome who may resume regular cycles as their metabolic health improves.

“Being at a higher BMI is associated with things like insulin resistance, sleep apnea, and hypertension,” said Christina Boots, a reproductive endocrinologist at Northwestern Medicine in Chicago and co-author of a narrative review on obesity, GLP-1 medications, and reproductive health.

“So even if it’s not severe, maybe GLP-1s are having subtle effects on uterine perfusion and inflammation and other things,” said Boots.

GLP-1 Receptor Agonists in Reproductive Health — Boston IVF

Reviewing reproductive health for prescriptions

Before prescribing a GLP-1 to a patient of childbearing age, clinicians must conduct a thorough intake covering reproductive health and family planning goals. Doctors need to establish whether the patient is hoping to get pregnant soon, later, or not at all, while reviewing menstrual regularity and signs of anovulation.

Physicians also evaluate histories of polyendocrine metabolic ovarian syndrome, gestational diabetes, preeclampsia, or previous adverse pregnancy outcomes. Current contraception methods must be reviewed alongside potential risks for missed doses caused by gastrointestinal side effects such as vomiting and diarrhea.

“If they’re on these medications and they’re not trying to conceive, get them on contraception,” said Stacey Ehrenberg, director of Diabetes in Pregnancy at the Cleveland Clinic. “There’s no reason not to, and then it’s a nonissue.”

GLP-1 drugs harming your Reproductive health? — Dr. Jennifer Lincoln

“If they are trying to conceive, then involve the obstetric team and the maternal-fetal medicine team and the dietitian team early, so that when they become pregnant, there’s a seamless transition,” said Ehrenberg.

Switching contraception before pregnancy

Gastrointestinal side effects frequently compromise the reliability of oral contraceptives. Furthermore, tirzepatide specifically reduces the bioavailability of oral birth control pills, requiring patients experiencing significant side effects to switch to non-oral contraceptives or add barrier methods.

Because GLP-1 drugs have not been proven safe during pregnancy, patients planning to conceive must stop taking them. Semaglutide labeling recommends discontinuing the medication two months before a planned pregnancy to account for the drug’s long half-life, though consensus guidelines advise stopping use only after a positive pregnancy test to prevent premature weight regain.

“I’ve seen patients who were like, ‘Okay, I’m stopping my meds Jan. 1,’ and then they don’t get pregnant,” Boots said. “By April they’ve gained 20 pounds back because they weren’t supported, and they’re pretty distressed about one, having some delayed conception, but also because they’ve gained the weight back, and now they’re not cycling as well.”

Managing Discontinuation and Postpartum Cardiometabolic Health

Limited observational data on inadvertent early exposure to GLP-1 medications show no increased risk to the fetus, meaning a positive pregnancy test should prompt discontinuation and follow-up rather than panic. Patients who stop treatment during the first month need standard prenatal growth monitoring, enrollment in drugmaker exposure registries, and referrals to maternal-fetal medicine specialists.

For patients managing existing diabetes, stopping GLP-1 therapy causes blood glucose levels to rise rapidly, necessitating immediate coordination with endocrinology teams. For patients treating obesity, discontinuation frequently triggers weight regain that requires nutritional counseling and mental health support to address distress.

Postpartum prescriptions for GLP-1 medications have risen sharply, offering a potential window for cardiometabolic prevention in patients with histories of gestational diabetes or preeclampsia.

“There are very few fields where a patient’s cardiometabolic trajectory completely changes within 9 months,” said Zainab Mahmoud, an assistant professor of cardiology and OB/GYN at Washington University in St. Louis.

“A patient can go into pregnancy at a normal weight and come out of pregnancy with either overweight or obesity, and that will be a different trajectory for her for the rest of her life,” said Mahmoud.

Answering medication safety questions

Are GLP-1 medications safe to use while breastfeeding?

Safety data regarding GLP-1 use during lactation remain scant, though existing information suggests potential safety. Clinical consensus advises balancing breastfeeding benefits against theoretical infant exposure risks while closely monitoring maternal nutrition, hydration, and infant developmental milestones.

What specific birth control methods work best with tirzepatide?

Because tirzepatide reduces oral contraceptive bioavailability, patients taking the medication must switch to non-oral contraceptives or add a barrier method after starting treatment and following each dose increase.

How do clinicians monitor patients with prior gestational diabetes after stopping GLP-1s?

Patients discontinuing GLP-1 medications require urgent follow-up with maternal-fetal medicine or endocrinology teams to prevent dangerous gaps in blood glucose management and ensure tight glycemic control during early pregnancy.

About the author: Dr Natalie Singh - Health Editor

Board‑certified internal‑medicine physician and MPH. Natalie authored peer‑reviewed studies on infectious disease and served as medical editor. “Dr. Natalie Singh delivers evidence‑based health news, medical breakthroughs, and expert wellness guidance.”